Observation of Alectinib‐ and Crizotinib‐ included chemotherapy in children with ALK‐positive anaplastic large cell lymphoma: A single institutional experience - He, Yingyi; Pei, Kunlin; Zhang, Hui; Wang, Jiayi; Su, Xiaoling; Gan, Wenting; Wang, Pengfei (Cancer medicine (Malden, MA), 2023)
Keywords: ALK inhibitor; ALK‐positive; Anaplastic large-cell lymphoma; Anaplastic Lymphoma Kinase; Bone marrow; Brain cancer; Brief Communication; Chemotherapy; Child; childhood; Children & youth; Crizotinib - therapeutic use; FDA approval; Females; Humans; Inhibitor drugs; Lung Neoplasms - pathology; Lymphatic system; Lymphoma; Lymphoma, Large-Cell, Anaplastic - drug therapy; Lymphoma, Large-Cell, Anaplastic - pathology; Neoplasm Recurrence, Local - drug therapy; outcome; Patients; Pediatrics; Pericardium; Protein Kinase Inhibitors - adverse effects; Remission; Remission (Medicine); Risk groups; Targeted cancer therapy; ALK-positive; anaplastic large cell lymphoma; ALK inhibitor; childhood; outcome